Stay updated on Pembrolizumab in Advanced Head and Neck Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced Head and Neck Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced Head and Neck Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.4%
- Check18 days agoChange DetectedThe web page has been updated to include detailed information about a Phase III clinical study evaluating pembrolizumab as a treatment for Stage III-IVA resectable locoregionally advanced head and neck squamous cell carcinoma. Key details such as study design, eligibility criteria, and locations for participation have been added.SummaryDifference100%
- Check25 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed study information regarding a clinical trial for pembrolizumab in treating advanced head and neck squamous cell carcinoma. This includes critical data on study design, eligibility criteria, and locations involved in the trial.SummaryDifference91%
- Check32 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.6%
- Check39 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab in Advanced Head and Neck Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced Head and Neck Clinical Trial page.